Salute e Benessere

Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug…

VANCOUVER, BC, May 24, 2024 /PRNewswire/ -- USA News GroupNews Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 to June 4, industry leaders will unveil new data on late-stage and approved therapies. Recent FDA approvals are also enriching the treatment landscape, offering patients innovative and improved cancer therapies…

Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of…

Hugues Lecat appointed Chairman of the Board of Directors of GuerbetVillepinte, 24 May 2024:Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, is announcing the appointment of Hugues Lecat as Chairman of the Board of Directors, in accordance with the previously announced timetable (press release of 20 March 2024).Following the approval of his appointment as director at the Annual General Meeting held today at the registered...

Casino Group: Judgment on FRH and Casino request for further extension under…

Judgment on FRH and Casino request for further extension under Dutch Financial Supervision Act Paris, 24 May 2024Casino Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR0000125585, "Casino") hereby informs as follows: also on behalf of France Retail Holdings S.à r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that FRH and Casino have received a judgment of the Enterprise Chamber of the Amsterdam Court of Appeal, the Netherlands…

BioSenic provides First Quarter 2024 Business Update

PRESS RELEASE – REGULATED INFORMATIONMont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET –BioSenic(Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces its business update for the first quarter, ended 31 March 2024.Key highlights In January 2024, BioSenic signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds facility, arranged by ABO...

Positive data from phase 2 NOBLE study of pegcetacoplan presented as…

At one year, of the 11 pegcetacoplan-treated patients with available data: At one year, of the 11 pegcetacoplan-treated patients with available data: Excessive C3c deposits are a marker of disease activity, which can lead to kidney inflammation, damage, and failure. Clearance of both C3c deposits and inflammation allow the kidney to recover and prolong the function of the kidney. Additionally, treatment with pegcetacoplan resulted in sustained improvements in key measures of...

Biopreservation Market Worth $7.1 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=842 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=842 Browse in-depth TOC on "Biopreservation Market" 361 - Tables53 - Figures315 - Pages Biopreservation Market Scope: The biopreservation media segment is expected to account for the largest share in 2023. The Biopreservation market, by product, has been segmented into...

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer…

LOS ANGELES and AMSTERDAM, May24, 2024(GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the...

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in…

SAN DIEGO and CALGARY, AB, May 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed…

61st ERA Congress: Semaglutide significantly reduces risk of major kidney…

Participants who received semaglutide had a 24% risk reduction for the composite primary endpoint, including kidney outcomes and death due to cardiovascular and kidney causes, compared to those who received placebo. This reduction risk was consistent across both kidney-specific and cardiovascular death outcomes. Participants who received semaglutide had a 24% risk reduction for the composite primary endpoint, including kidney outcomes and death due to cardiovascular and kidney causes…

Minutes of Annual General Meeting 2024

All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on www.pcibiotech.com.Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, [email protected], Mobile: +47 9400 5757This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. Attachment PCI Biotech Holding ASA...

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination…

The ELECTRA study is evaluating elacestrant in combination with abemaciclib in patients with ER+, HER2- metastatic breast cancer with brain metastases; however, the phase 1b portion of this study was conducted in all metastatic sites, including brain metastases. The updated phase 1b results continue to show a satisfactory safety profile, consistent with prior findings, and promising activity in patients with ER+, HER2- advanced or mBC regardless of metastatic site. Based on the results…

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA…

CAMBRIDGE, England, May 24, 2024 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it will be presenting interim clinical data on its first-in-class lead product, STC-15 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, US from May 31 to June 4, 2024. CAMBRIDGE, England,May 24, 2024/PRNewswire/ -- STORM Therapeutics…

Lift BioSciences Announces Abstract Publications at the American Society of…

Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual MeetingLondon, 24 May 2024– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announces the publication of two online abstracts at the annual American Society of Clinical Oncology, to be held from 31 May to 4 June 2024 in McCormick Place Convention Centre in...

Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024

Press ReleaseNicox: 2024 Ordinary Shareholder Meeting to be held on June 28 th, 2024May 24, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, convenes an ordinary shareholder meeting onFriday June 28 th, 2024 at 2:30 pm CESTin the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.The documents...

ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE

This capital increase complies with the ceiling established within the company's Articles of Association and does not require any statutory change. The capital increase will be carried out through the issuance of 115.4 million new registered ordinary shares with no par value. This capital increase complies with the ceiling established within the company's Articles of Association and does not require any statutory change. The capital increase will be carried out through the issuance of 115...

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine…

EVX-01 induced positiveclinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both CD4+ and CD8+ T-cellsCOPENHAGEN, Denmark, May23, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces its participation in the American...

Genmab to Showcase Data in Various Patient Populations to be Presented at the…

Media ReleaseCOPENHAGEN, Denmark; May 23, 2024 Six oral and poster presentations will highlight breadth of clinical program and potential utility of epcoritamab-bysp in patients with difficult-to-treat lymphomas across multiple lines of therapy and histologies where high unmet needs existResults from two studies evaluating tisotumab vedotin in patients with head and neck squamous cell carcinoma and recurrent or metastatic cervical cancer accepted for oral and poster presentations,...

Philips successfully prices offering of Notes for EUR 700 million to be used for…

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 700 million fixed rate notes due 2032 (the “Notes”) under its European Medium Term Note (EMTN) program.The issue of the Notes will have a debt-neutral effect, as the net proceeds of the transaction will be used for repayment of debt in 2024 and 2025.The issue price for the Notes is 98.257% with a Coupon of 3...

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

PARIS and CAMBRIDGE, Mass., May23, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event. Jefferies Global Healthcare Conference Date:...

Zealand Pharma announces topline results from the mechanistic investigator-led…

Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutideMean weight loss of up to 4.3% after 12 weeks with low doses of dapiglutide treatment Dapiglutide was assessed to be well-toleratedTolerability profile observed suggests doses investigated were at the lower end of the therapeutic rangeMuch higher doses of dapiglutide are being investigated in...

Photocure ASA - Annual general meeting held

For further information, please contact: For further information, please contact: Photocure CFOErik DahlTel: + 47 450 55 000 Email:[email protected] About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered inOslo, Norway, and listed on the...

Hornet Therapeutics emerges from stealth with data published in Science…

Press ReleaseHornet Therapeutics emerges from stealth with data published inSciencedemonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease 4BIO Capital incubated company launches with the first ever small molecule drug that has potential for treating EBV-driven diseasesNew data demonstrates decreased EBV latency upon inhibition of the host metabolic enzyme IDO-1 in target cellsThe company emerges from stealth with a strategic...

Oxurion Announces Results on the Annual Shareholders' Meeting of 16 May 2024

Oxurion Announces Results on the Annual Shareholders' Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET– Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders' meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders' meeting.All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion's website...

Global Sugar Alcohol Market to Scale Beyond $2.46 Billion with 5.9% CAGR by 2034…

Consumption of food and drinks prepared with sugar alcohols rather than ordinary sugar is rising due to the rising prevalence of diabetes, as these products are detrimental to those who already have such a condition. A lot of people have begun using sugar alcohol to manage their weight and blood sugar levels. Sugar alcohols are becoming popular replacements for sucrose and high-fructose corn syrup because they add sweetness without having the same negative metabolic effects. Consumption of…

Altri Comunicati